Literature DB >> 11226576

Modification of virus infectivity by cytoplasmic tail of HIV-1 TM protein.

Y Iwatani1, T Ueno, A Nishimura, X Zhang, T Hattori, A Ishimoto, M Ito, H Sakai.   

Abstract

Envelope glycoprotein incorporation is an essential process in formation of infectious particles of human immunodeficiency virus. Accumulated data have indicated that the cytoplasmic tail of Env gp41 is required for efficient incorporation. By analyzing mutant viruses with truncated cytoplasmic tails, we found that the domain was required in a cell-type-dependent manner for maintaining virus infectivity. Although the viruses with truncated cytoplasmic tails produced from HeLa, A3.01 and SupT1 cells showed a greatly reduced infectivity, those from SW480 and MT-4 cells retained a significant infectivity. To clarify the different effect of the cytoplasmic tail mutation on virus infectivity, we performed biochemical studies on the virions produced from HeLa and SW480 cells. Although the truncation of cytoplasmic tail appeared to reduce the Env incorporation in both cell lines, it caused a significant incorporation of Env precursor with HeLa cells. The results suggested that the cytoplasmic tail regulated selective incorporation of processed Env into virions in a cell-type-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11226576     DOI: 10.1016/s0168-1702(00)00249-5

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  10 in total

1.  The membrane-proximal tyrosine-based sorting signal of human immunodeficiency virus type 1 gp41 is required for optimal viral infectivity.

Authors:  John R Day; Carsten Münk; John C Guatelli
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

2.  Murine leukemia virus R Peptide inhibits influenza virus hemagglutinin-induced membrane fusion.

Authors:  Min Li; Zhu-Nan Li; Qizhi Yao; Chinglai Yang; David A Steinhauer; Richard W Compans
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

Review 3.  HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation.

Authors:  Mary Ann Checkley; Benjamin G Luttge; Eric O Freed
Journal:  J Mol Biol       Date:  2011-07-22       Impact factor: 5.469

4.  HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores.

Authors:  Blandine Monel; Elodie Beaumont; Daniela Vendrame; Olivier Schwartz; Denys Brand; Fabrizio Mammano
Journal:  J Virol       Date:  2012-01-18       Impact factor: 5.103

5.  Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail.

Authors:  Jiyang Jiang; Christopher Aiken
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

6.  Retroviral env glycoprotein trafficking and incorporation into virions.

Authors:  Tsutomu Murakami
Journal:  Mol Biol Int       Date:  2012-07-02

Review 7.  The frantic play of the concealed HIV envelope cytoplasmic tail.

Authors:  Eveline Santos da Silva; Martin Mulinge; Danielle Perez Bercoff
Journal:  Retrovirology       Date:  2013-05-24       Impact factor: 4.602

8.  The Envelope Cytoplasmic Tail of HIV-1 Subtype C Contributes to Poor Replication Capacity through Low Viral Infectivity and Cell-to-Cell Transmission.

Authors:  Eveline Santos da Silva; Martin Mulinge; Morgane Lemaire; Cécile Masquelier; Cyprien Beraud; Arkadiusz Rybicki; Jean-Yves Servais; Gilles Iserentant; Jean-Claude Schmit; Carole Seguin-Devaux; Danielle Perez Bercoff
Journal:  PLoS One       Date:  2016-09-06       Impact factor: 3.240

9.  Super-resolution microscopy reveals specific recruitment of HIV-1 envelope proteins to viral assembly sites dependent on the envelope C-terminal tail.

Authors:  Walter Muranyi; Sebastian Malkusch; Barbara Müller; Mike Heilemann; Hans-Georg Kräusslich
Journal:  PLoS Pathog       Date:  2013-02-28       Impact factor: 6.823

Review 10.  Cytopathic mechanisms of HIV-1.

Authors:  Joshua M Costin
Journal:  Virol J       Date:  2007-10-18       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.